SV2011003828A - Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) - Google Patents

Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)

Info

Publication number
SV2011003828A
SV2011003828A SV2011003828A SV2011003828A SV2011003828A SV 2011003828 A SV2011003828 A SV 2011003828A SV 2011003828 A SV2011003828 A SV 2011003828A SV 2011003828 A SV2011003828 A SV 2011003828A SV 2011003828 A SV2011003828 A SV 2011003828A
Authority
SV
El Salvador
Prior art keywords
tfpi
monoclonal antibodies
inhibitor
antibodies against
factor via
Prior art date
Application number
SV2011003828A
Other languages
English (en)
Inventor
Zhuozhi Wang
John E Murphy
Junliang Pan
Haiyan Jiang
Liu Bing
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41664165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2011003828(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SV2011003828A publication Critical patent/SV2011003828A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PROPORCIONAN ANTICUERPOS MONOCLONALES AISLADOS QUE SE UNEN AL INHIBIDOR DE LA VÍA DEL FACTOR TISULAR (TFPI) HUMANO Y LAS MOLÉCULAS DE ACIDO NUCLEICO AISLADAS QUE LOS CODIFICAN. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS ANTICUERPOS MONOCLONALES ANTI-TFPI Y PROCEDIMIENTOS PARA TRATAR DEFICIENCIAS O DEFECTOS DE LA COAGULACIÓN MEDIANTE ADMINISTRACIÓN DE LOS ANTICUERPOS. TAMBIÉN SE PROPORCIONAN PROCEDIMIENTOS PARA PRODUCIR LOS ANTICUERPOS
SV2011003828A 2008-08-04 2011-02-04 Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) SV2011003828A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8598008P 2008-08-04 2008-08-04

Publications (1)

Publication Number Publication Date
SV2011003828A true SV2011003828A (es) 2011-05-20

Family

ID=41664165

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003828A SV2011003828A (es) 2008-08-04 2011-02-04 Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)

Country Status (35)

Country Link
US (3) US20120269817A1 (es)
EP (1) EP2321356B1 (es)
JP (1) JP5801194B2 (es)
KR (5) KR20190099341A (es)
CN (4) CN105944100B (es)
AU (3) AU2009279804C1 (es)
BR (2) BRPI0917418A2 (es)
CA (4) CA3138035A1 (es)
CL (3) CL2011000230A1 (es)
CO (1) CO6351803A2 (es)
CR (1) CR20110066A (es)
CU (2) CU23880B1 (es)
CY (1) CY1120670T1 (es)
DK (1) DK2321356T3 (es)
DO (2) DOP2011000045A (es)
EC (1) ECSP11010810A (es)
ES (1) ES2677329T3 (es)
HR (1) HRP20181095T1 (es)
HU (1) HUE038648T2 (es)
IL (4) IL210987A (es)
LT (1) LT2321356T (es)
MX (1) MX2011001351A (es)
MY (1) MY161844A (es)
NZ (2) NZ714313A (es)
PE (2) PE20110771A1 (es)
PH (1) PH12017502286A1 (es)
PL (1) PL2321356T3 (es)
PT (1) PT2321356T (es)
SG (1) SG10201703066PA (es)
SI (1) SI2321356T1 (es)
SV (1) SV2011003828A (es)
TR (1) TR201807252T4 (es)
UA (2) UA112050C2 (es)
WO (1) WO2010017196A2 (es)
ZA (1) ZA201100888B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2379096T3 (da) 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
PL2379600T5 (pl) * 2008-12-22 2021-03-08 Novo Nordisk A/S Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego
RS61082B1 (sr) * 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
AU2013202745B2 (en) * 2010-03-01 2017-01-05 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
AU2016269554B2 (en) * 2010-03-01 2018-12-20 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2542257B1 (en) * 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
CN103080135B (zh) * 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
HUE042706T2 (hu) * 2011-04-01 2019-07-29 Bayer Healthcare Llc Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen
HUE046572T2 (hu) 2012-03-21 2020-03-30 Baxalta GmbH TFPI inhibitorok és alkalmazási eljárások
AU2013240279A1 (en) * 2012-03-30 2014-10-16 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6454678B2 (ja) 2013-03-15 2019-01-16 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ ｐＨ範囲で結合性が異なる薬物動態改善のための抗ＴＦＰＩ抗体変異体
CN105473619B (zh) * 2013-07-19 2020-12-15 诺和诺德股份有限公司 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
WO2016137108A1 (en) * 2015-02-25 2016-09-01 Mogam Biotechnology Institute Novel antibody binding to tfpi and composition comprising the same
MY195443A (en) 2015-08-19 2023-01-21 Pfizer Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
JP6419664B2 (ja) * 2015-08-26 2018-11-07 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
WO2020075083A1 (en) 2018-10-11 2020-04-16 Pfizer Inc. Dosage regimen for tfpi antagonists
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN112552396B (zh) * 2020-12-30 2022-07-12 河南中泽生物工程有限公司 抗非洲猪瘟病毒p54蛋白单克隆抗体、制备方法及应用
JP2021091720A (ja) * 2021-03-03 2021-06-17 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) * 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US20040052799A1 (en) * 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
JP2002505871A (ja) * 1998-03-12 2002-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３１個のヒト分泌タンパク質
JP2000128803A (ja) * 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
JP4623825B2 (ja) * 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) * 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CA2406583A1 (en) * 2000-05-10 2001-11-15 Novo Nordisk A/S Pharmaceutical composition comprising a factor viia and a factor xiii
US20020082206A1 (en) * 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) * 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
EP1379549A2 (fr) * 2001-02-07 2004-01-14 Institut Pasteur Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
US6891085B2 (en) * 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
EP1390507A2 (en) * 2001-05-21 2004-02-25 Ecopia Biosciences Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2002365131B2 (en) * 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
EP1468118A4 (en) * 2002-01-31 2006-08-02 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
AU2003222249A1 (en) * 2002-03-04 2003-09-22 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
CA2483909A1 (en) * 2002-05-01 2003-11-13 Schering Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2490280A1 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
DE10239073A1 (de) * 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
EP3299465A1 (en) * 2003-03-07 2018-03-28 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
DE602004026474D1 (de) * 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
EP2298797A3 (en) * 2004-01-09 2011-05-18 Novozymes Inc. Increased bacillus YweA expression
CN105085678B (zh) * 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP3520815B1 (en) * 2005-02-08 2021-11-17 Genzyme Corporation Antibodies to tgfbeta
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
EP1871883A1 (en) * 2005-03-02 2008-01-02 Metanomics GmbH Process for the production of fine chemicals
KR101434682B1 (ko) * 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
AU2007260787A1 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
PL2379600T5 (pl) * 2008-12-22 2021-03-08 Novo Nordisk A/S Przeciwciała przeciwko inhibitorowi szlaku czynnika tkankowego
EP2542257B1 (en) * 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Also Published As

Publication number Publication date
IL210987A0 (en) 2011-04-28
CA3081514A1 (en) 2010-02-11
PE20141563A1 (es) 2014-10-24
UA120596C2 (uk) 2020-01-10
ES2677329T3 (es) 2018-08-01
US20120269817A1 (en) 2012-10-25
UA112050C2 (uk) 2016-07-25
JP2013500701A (ja) 2013-01-10
PH12017502286A1 (en) 2019-11-11
CA2933259A1 (en) 2010-02-11
KR20110043736A (ko) 2011-04-27
CR20110066A (es) 2011-05-25
TR201807252T4 (tr) 2018-06-21
IL277162A (en) 2020-10-29
KR20180029106A (ko) 2018-03-19
CN102143979A (zh) 2011-08-03
CU23880B1 (es) 2013-04-19
CN105944100B (zh) 2019-09-17
HUE038648T2 (hu) 2018-11-28
IL210987A (en) 2017-03-30
CY1120670T1 (el) 2019-12-11
AU2009279804B2 (en) 2016-03-24
CA2733075A1 (en) 2010-02-11
CL2016003014A1 (es) 2017-06-30
LT2321356T (lt) 2018-09-10
AU2009279804A1 (en) 2010-02-11
ZA201100888B (en) 2012-04-25
CA3138035A1 (en) 2010-02-11
KR20190099341A (ko) 2019-08-26
CU23900B1 (es) 2013-03-28
DOP2019000287A (es) 2019-12-15
AU2016201230A1 (en) 2016-03-17
KR20160091439A (ko) 2016-08-02
ECSP11010810A (es) 2011-03-31
IL277162B (en) 2021-05-31
US20180334509A1 (en) 2018-11-22
CO6351803A2 (es) 2011-12-20
PL2321356T3 (pl) 2018-10-31
CN110437335A (zh) 2019-11-12
DOP2011000045A (es) 2011-10-31
KR101692085B1 (ko) 2017-01-03
CA3081514C (en) 2021-12-14
CA2733075C (en) 2018-10-23
MY161844A (en) 2017-05-15
HRP20181095T1 (hr) 2018-09-21
IL282658A (en) 2021-06-30
IL250640A0 (en) 2017-04-30
CU20110031A7 (es) 2012-06-21
KR20170005516A (ko) 2017-01-13
DK2321356T3 (en) 2018-07-23
CL2011000230A1 (es) 2011-06-24
CN102143979B (zh) 2016-08-03
MX2011001351A (es) 2011-10-12
SG10201703066PA (en) 2017-05-30
WO2010017196A2 (en) 2010-02-11
EP2321356B1 (en) 2018-04-11
BRPI0917418A2 (pt) 2021-01-05
CA2933259C (en) 2021-07-06
NZ714313A (en) 2017-05-26
US20170342162A1 (en) 2017-11-30
PT2321356T (pt) 2018-07-17
AU2009279804C1 (en) 2017-01-19
BR122017025538A2 (pt) 2021-01-19
EP2321356A4 (en) 2013-02-13
AU2018203753A1 (en) 2018-06-21
CN105944100A (zh) 2016-09-21
EP2321356A2 (en) 2011-05-18
IL250640B (en) 2020-10-29
KR101769725B1 (ko) 2017-08-18
PE20110771A1 (es) 2011-10-14
CU20110236A7 (es) 2012-07-31
NZ731392A (en) 2018-10-26
JP5801194B2 (ja) 2015-10-28
WO2010017196A3 (en) 2010-11-04
CL2016003015A1 (es) 2017-06-30
SI2321356T1 (sl) 2018-09-28
CN110452299A (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
SV2011003828A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
DOP2013000218A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
CO6321234A2 (es) Derivados de acido fenilacetico como moduladores de la inflamacion
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
CY1114276T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας